Veterinary Medicines

DIVENCE IBR Marker Live Lyophilisate and solvent for suspension for injection

Authorised
  • Bovine herpesvirus 1, strain CEDDEL, gE- tk- double-gene deleted, Live
Download as PDF

Product identification

Medicine name:
DIVENCE IBR Marker Live Lyophilisate and solvent for suspension for injection
Active substance:
  • Bovine herpesvirus 1, strain CEDDEL, gE- tk- double-gene deleted, Live
Target species:
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine herpesvirus 1, strain CEDDEL, gE- tk- double-gene deleted, Live
    Presentation_strength:10⁶·³ - 10⁷·⁶ CCID50 Comments:lyophilisate Index:0
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • All relevant tissues
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Lyophilisate: vial (glass); Solvent; vial (PET), Package_size:Lyophlisate: 1 vial + Solvent: 1 vial, Content:Lyophilisate: 5 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); Solvent; vial (PET), Package_size:Lyophlisate: 1 vial + Solvent: 1 vial, Content:Lyophilisate: 20 doses; solvent: 40 ml
  • Packaging:Lyophilisate: vial (glass); Solvent; vial (PET), Package_size:Lyophlisate: 1 vial + Solvent: 1 vial, Content:Lyophilisate: 50 doses; solvent: 100 ml
  • Packaging:Lyophilisate: vial (glass); Solvent; vial (PET), Package_size:Lyophlisate: 1 vial + Solvent: 1 vial, Content:Lyophilisate: 40 doses; solvent: 80 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - known active substance (Article 8 of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • LABORATORIOS HIPRA, S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 9/09/2025
Download
Bulgarian (PDF)
Published on: 9/09/2025
Download
Croatian (PDF)
Published on: 9/09/2025
Download
Czech (PDF)
Published on: 9/09/2025
Download
Danish (PDF)
Published on: 9/09/2025
Download
Dutch (PDF)
Published on: 9/09/2025
Download
Estonian (PDF)
Published on: 9/09/2025
Download
Finnish (PDF)
Published on: 9/09/2025
Download
French (PDF)
Published on: 9/09/2025
Download
German (PDF)
Published on: 9/09/2025
Download
Greek (PDF)
Published on: 9/09/2025
Download
Hungarian (PDF)
Published on: 9/09/2025
Download
Icelandic (PDF)
Published on: 9/09/2025
Download
Italian (PDF)
Published on: 9/09/2025
Download
Latvian (PDF)
Published on: 9/09/2025
Download
Lithuanian (PDF)
Published on: 9/09/2025
Download
Maltese (PDF)
Published on: 9/09/2025
Download
Norwegian (PDF)
Published on: 9/09/2025
Download
Polish (PDF)
Published on: 9/09/2025
Download
Portuguese (PDF)
Published on: 9/09/2025
Download
Romanian (PDF)
Published on: 9/09/2025
Download
Slovak (PDF)
Published on: 9/09/2025
Download
Slovenian (PDF)
Published on: 9/09/2025
Download
Spanish (PDF)
Published on: 9/09/2025
Download
Swedish (PDF)
Published on: 9/09/2025
Download

ema-puar-v6260-divenceibrmarkerlive-en.pdf

English (PDF)
Published on: 22/10/2024
Download